RxDoctor Payments Data

Deborah Malters, MD

Psychiatry · Billings, MTNPI 1487697876

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 45.1% of the total.

$284in general payments, 2019–2025

Across 17 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$128
  • Novo Nordisk$32
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$32
  • Johnson & Johnson$28
  • Supernus Pharmaceuticals, Inc.$21
  • Neurocrine Biosciences, Inc.$16
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$284100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$284 in reported general payments places this provider in the 65th percentile of 82 psychiatry providers in Montana.

See all psychiatry providers in Montana

Medicare billing

Part B allowed, 2024
$47,629
Medicare patients
57
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole20$28,505
CaplytaLumateperone Tosylate32$26,123
Chlorpromazine Hcl35$9,182
FetzimaLevomilnacipran Hcl15$6,551
Aripiprazole114$5,199
Desvenlafaxine Succinate ErDesvenlafaxine Succinate50$4,508
Quetiapine Fumarate128$3,382
Bupropion XlBupropion Hcl82$2,137
Duloxetine Hcl136$2,119
Gabapentin105$1,991
Olanzapine87$1,741
Quetiapine Fumarate ErQuetiapine Fumarate20$1,422
Modafinil34$1,069
Methylphenidate Hcl38$925
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine30$912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$32$26,12332 claims
AbbVieFetzima$128$6,55115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 82 psychiatry providers in Montana.

Other psychiatry in Billings

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →